Table 1 Clinical characteristics in patients with FMD <4.2 % and ≥4.2 %
|  | FMD <4.2 % (n = 40 ) | FMD ≥ 4.2 % (n = 40) | p |
|---|---|---|---|
Age (years) | 69.5 ± 7.1 | 69.4 ± 7.3 | 0.96 |
Female gender, n (%) | 34 (85.0) | 30 (75.0) | 0.26 |
Body mass index | 25.1 ± 3.4 | 23.6 ± 3.3 | 0.06 |
Diabetes mellitus, n (%) | 23 (57.5) | 22 (55.0) | 0.82 |
Hypertension, n (%) | 27 (65.7) | 27 (67.5) | 1.00 |
Dyslipidemia, n (%) | 22 (55.0) | 31 (77.5) | 0.03 |
Current smoking, n (%) | 10 (25.0) | 11 (27.5) | 0.80 |
Chronic renal insufficiency, n (%) | 16 (40.0) | 19 (47.5) | 0.50 |
Previous PCI, n (%) | 5 (12.5) | 10 (25.0) | 0.15 |
Previous myocardial infarction, n (%) | 2 (5.0) | 2 (5.0) | 1.00 |
HDL cholesterol (mg/dl) | 43.8 ± 11.2 | 49.3 ± 12.3 | 0.04 |
LDL cholesterol (mg/dl) | 87.8 ± 28.1 | 88.1 ± 24.6 | 0.96 |
Triglycerides (mg/dl) | 142.9 ± 73.6 | 113.7 ± 61.6 | 0.06 |
MDA-LDL cholesterol | 97.9 ± 36.8 (n = 33) | 82.2 ± 32.0 (n = 27) | 0.62 |
Adiponectin | 11.3 ± 5.2 | 12.0 ± 5.3 | 0.90 |
Medications | Â | Â | Â |
Aspirin, n (%) | 40 (100) | 38 (95.0) | 0.15 |
Clopidogrel, n (%) | 35 (87.5) | 33 (82.5) | 0.53 |
ACE inhibitor/ARB, n (%) | 35 (87.5) | 30 (75.0) | 0.15 |
ARB, n (%) | 31 (77.5) | 25 (62.5) | 0.22 |
ACE inhibitors, n (%) | 4 (10.0) | 5 (12.5) | 0.99 |
Perindopril | 2 (5.0) | 1 (2.5) | 0.99 |
Imidapril | 2 (5.0) | 4 (10.0) | 0.67 |
Statins, n (%) | 36 (90.0) | 36 (90.0) | 1.00 |
Atorvastatin | 4 (10.0) | 7 (17.5) | 0.52 |
Rosuvastatin | 18 (45.0) | 16 (40.0) | 0.82 |
Pitavastaitn | 14 (35.0) | 13 (32.5) | 0.99 |
β-blockers, n (%) | 21 (52.5) | 25(62.5) | 0.37 |